Does Rallies show Form 4 insider transactions for OMER?

Yes. Rallies tracks OMER insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is OMER research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OMER. It does not provide personalized investment advice.

OMER (Omeros Corporation) Stock Analysis - Insider Trades

Omeros Corporation (OMER) is a publicly traded Healthcare sector company. As of May 21, 2026, OMER trades at $12.43 with a market cap of $846.79M and a P/E ratio of 9.45. OMER moved +3.43% today. Year to date, OMER is -19.61%; over the trailing twelve months it is +276.29%. Its 52-week range spans $2.95 to $17.65. Analyst consensus is buy with an average price target of $40.00. Rallies surfaces OMER's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading OMER stock inside the company?

Recent OMER insider activity includes Borges David J. sold 30.00K, Borges David J. sold 30.00K, Demopulos Gregory A MD bought 15.00K, Demopulos Peter A MD bought 10.00K, and HANISH ARNOLD C sold 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

OMER Key Metrics

Key financial metrics for OMER
Metric	Value
Price	$12.43
Market Cap	$846.79M
P/E Ratio	9.45
EPS	$1.30
Dividend Yield	0.00%
52-Week High	$17.65
52-Week Low	$2.95
Volume	984
Avg Volume	0
Revenue (TTM)	$9.89M
Net Income	$86.17M
Gross Margin	0.00%

Recent OMER Insider Trades

Borges David J. sold 30.00K (~$369.31K) on Jan 13, 2026.
Borges David J. sold 30.00K (~$381.60K) on Jan 12, 2026.
Demopulos Gregory A MD bought 15.00K (~$25.20K) on Nov 17, 2023.
Demopulos Peter A MD bought 10.00K (~$15.30K) on Nov 15, 2023.
HANISH ARNOLD C sold 5.00K (~$32.30K) on May 22, 2023.

Latest OMER News

Omeros Reports Q1 Net Income of $56.1M, Launches YARTEMLEA for TA-TMA — May 14, 2026
Omeros Analysts See 266.7% Upside with $43.67 Price Target — Apr 11, 2026
Omeros Launches Yarcomlia at $36,000 per Dose, Secures Supply Through 2029 — Jan 9, 2026

OMER Analyst Consensus

2 analysts cover OMER: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $40.00.

Common questions about OMER

Who is trading OMER stock inside the company?: Recent OMER insider activity includes Borges David J. sold 30.00K, Borges David J. sold 30.00K, Demopulos Gregory A MD bought 15.00K, Demopulos Peter A MD bought 10.00K, and HANISH ARNOLD C sold 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for OMER?: Yes. Rallies tracks OMER insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is OMER research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OMER. It does not provide personalized investment advice.